natgillin/translations-raw huggingface dataset:
The elimination t1/2 following intravenous dosing was approximately 5.8 h. 
Razpolovni čas izločanja po intravenskem odmerjanju je bil približno 5,8 h.
Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Evropske agencije za zdravila http://www.ema.europa.eu/
Each tablet contains 0.075% w/w Sunset Yellow (E110) as a colorant. 
Pomožne snovi: Vsaka tableta vsebuje 0,075 % w/w barvila sončno rumeno FCF (E110).
The volume of distribution at steady-state (Vss) was 2.3 l/kg and systemic clearance was 0.51 l/h/kg. 
Volumen porazdelitve v dinamičnem ravnovesju (Vss) je bil 2,3 l/kg in sistemski očistek je bil 0,51 l/h/kg.
Cerenia is not a sedative and some motion sick dogs may show nausea-like signs during travel such as salivation and lethargy. 
Cerenia ni sedativ in nekateri psi, občutljivi na vožnjo, lahko kažejo znake slabosti med vožnjo, kot je slinjenje in povečana zaspanost.
Signs of nausea in dogs including excessive salivation and lethargy might remain after treatment. 
Znaki slabosti pri psih, kot je povečano slinjenje in letargija, so lahko prisotni tudi po zdravljenju.
An unused half tablet should be returned to the opened blister and kept within the cardboard outer. 
Neporabljeno polovico tablete vrnite v pretisni omot in hranite v kartonski škatli.
To prevent vomiting, tablets should be given more than 1 hour in advance. 
Za preprečitev bruhanja dajemo tablete vsaj 1 uro vnaprej.
Products such as Cerenia should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon. 
Zdravila kot je Cerenia naj bi uporabljali v povezavi z ostalimi podpornimi terapijami, kot je kontrolirana dieta in terapija z nadomeščanjem tekočin, po priporočilu vašega veterinarja.
Signs of nausea including excessive salivation and lethargy might remain during treatment. 
Znaki slabosti, kot je povečano slinjenje in letargija, so lahko prisotni tudi med zdravljenjem.
Cerenia tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of the effect. 
Tablet Cerenia ne dajemo zavitih ali skritih v hrano, saj to lahko zadrži raztopitev tablete in posledično nastop učinka.
The safety of maropitant during treatment beyond 5 days has not been explored in the target population (i.e. young dogs suffering from viral enteritis). 
Varnost maropitanta pri zdravljenju v ciljni populaciji (npr. mladi psi, ki trpijo za virusnim eneteritisom), ki traja več kot 5 dni, ni bila raziskana.
Maropitant is non-sedative and should not be used as a sedative in motion sickness. 
Maropitant ni sedativ in se ne sme uporabljati za pomiritev pri slabosti zaradi vožnje.
To prevent vomiting, Cerenia solution for injection should be administered more than 1 hour in advance. 
Za preprečitev bruhanja dajemo Cerenia raztopino za injiciranje več kot 1 uro vnaprej.
Cerenia tablets are available in 16 mg, 24 mg, 60 mg and 160 mg strength. 
Cereina tablete so naslednjih jakosti: 16 mg, 24 mg, 60 mg ali 160 mg.
CYP1A and CYP3A-related enzymes were identified as the feline isoforms involved in the hepatic biotransformation of maropitant. 
CYP1A in encimi, povezani s CYP3A so potrjeni kot mačje izoforme, vključene v biotransformacijo maropitanta v jetrih.
The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%. 
Biorazpoložljivost maropitanta po subkutanem dajanju je 90,7 %.
Water for injections 
Metakrezol Voda za injekcije
Following repeated oral administration for two consecutive days at a daily dose of 8 mg/kg, accumulation was 218%. 
Pri ponavljajočem se peroralnem dajanju 2 zaporedna dneva, dnevni odmerek 8 mg/kg, je akumulacija 218 %.
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose. 
Zaradi velikega farmakokinetičnega razpona in akumulacije maropitanta v telesu po enkratni dnevni aplikaciji, so lahko, pri določenih živalih in ob ponovitvi odmerka, zadostni tudi nižji odmerki od priporočenih.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting. 
V skladu z dobro veterinarsko prakso se antiemetike uporablja v povezavi z ostalimi veterinarskimi in podpornimi terapijami, kot je dieta in tekočinska terapija, hkrati pa se zdravi osnovne vzroke bruhanja.
Pain at injection site may occur when injected subcutaneously. 
Na mestu injiciranja se lahko ob subkutanem injiciranju pojavi bolečina.
For the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces. 
V urinu najdemo 10,4 % oziroma v blatu 9,3 %
PACKAGE LEAFLET: Cerenia tablets for dogs 
NAVODILO ZA UPORABO Cerenia tablete za pse
Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sunset Yellow (E110) as a colorant 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi natrijev karmelozat, premreženi laktoza monohidrat magnezijev stearat celuloza, mikrokristalna sončno rumeno FCF (E110) kot barvilo 6.2 Glavne inkompatibilnosti
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Solution for injection 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla / Raztopina za injiciranje
The use of Cerenia solution for injection against vomiting due to motion sickness is not recommended. 
Uporabe raztopine za injiciranje Cerenia proti bruhanju, ki je posledica vožnje, ne priporočamo.
Each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate. 
Vsaka tableta vsebuje 16 mg, 24 mg, 60 mg ali 160 mg maropitanta v obliki maropitantijevega citrata monohidrata.
• For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures. 
• Za preprečevanje in zdravljenje bruhanja, v povezavi s Cerenia raztopino za injiciranje in v kombinaciji z ostalimi podpornimi terapijami.
In dogs, Cerenia solution for injection can be used to treat or prevent vomiting once daily for up to 5 days. 
Pri psih lahko raztopino za injiciranje Cerenia uporabite za zdravljenje ali preprečevanje bruhanja enkrat dnevno do 5 dni.
The duration of the effect is approximately 24 hours and, therefore, tablets can be given the night before administration of an agent that may cause emesis (e.g. chemotherapy). 
Učinek traja približno 24 ur, zato lahko tablete damo večer pred dajanjem zdravila, ki bi lahko povzročil slabost (na primer kemoterapija).
In some individual dogs and when repeating the treatment, lower doses than recommended might be sufficient. 
Pri določenih živalih so lahko ob ponovitvi odmerka zadostni tudi nižji odmerki od priporočenih.
Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family. 
Maropitant je antagonist neurokinin 1 (NK1) receptorja, ki inhibira vezavo substance P, tahikininskega neuropeptida.
• Find the pull-back notch (or cut) as shown by the arrow symbol . 
• poiščite zarezo za poteg, ki jo nakazuje simbol puščice 
• For the treatment and prevention of nausea induced by chemotherapy. 
• Za zdravljenje in preprečevanje slabosti, povzročene zaradi kemoterapije.
Cerenia 10 mg/ml solution for injection for dogs and cats is available in 20 ml amber glass vials. 
Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke je na voljo v 20 ml stekleni viali jantarjeve barve.
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight). 
Cerenia raztopino za injiciranje dajemo enkrat dnevno subkutano ali intravensko, v odmerku 1 mg/kg telesne mase (1 ml/10 kg telesne mase).
Dogs should be carefully observed following administration to ensure that each tablet is swallowed. 
Ko psu damo tableto, ga moramo opazovati, da se prepričamo, da je tableto pogoltnil.
Prolonged fasting before administration should be avoided. 
Podaljšan post pred aplikacijo ni priporočljiv.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Tablets 
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla / Tablete
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. 
Cerenia raztopino za injiciranje dajemo enkrat dnevno subkutano ali intravensko, v odmerku 1 mg/kg telesne mase (1 ml/10 kg telesne mase) do 5 zaporednih dni.
• For the treatment of vomiting, in combination with other supportive measures. 
• Za zdravljenje bruhanja v kombinaciji z ostalimi podpornimi terapijami.
• Remove tablet from blister and administer as instructed. 
• odstranite tableto iz pretisnega omota in jo dajte po navodilih.
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. 
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Bruhanje je lahko povezano z resnimi stanji, ki žival močno izčrpajo, vključno z gastrointestinalnimi obstrukcijami, zato je potrebno postaviti pravilno diagnozo.
To remove a tablet from the blister the following sequence should be carried out; 
NASVET O PRAVILNI UPORABI ZDRAVILA Za odstranitev tablete iz pretisnega omota upoštevajte naslednje zaporedje:
Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels. 
Ne uporabljajte zdravila Cerenia hkrati z antagonisti Ca kanalov, saj ima maropitant afiniteto do Ca kanalov.
Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range. 
Maropitant kaže linearno kinetiko po subkutanem dajanju v odmerku 0,25 - 3 mg/kg.
The tablets also contain Sunset Yellow (E110) as a colorant. 
Tablete vsebujejo tudi barvilo sončno rumeno FCF (E110).
With the extended use of Cerenia tablets in dogs from 5 to 14 consecutive days, the periodic safety update report (PSUR) cycle for Cerenia has been reset and the data lock point for the next PSUR is 30 June 2014 for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals. 
30. junij 2014 za oddajo 6 mesečnih poročil (ki zajema vse odobrene oblike zdravila) za naslednji dve leti, sledita letni poročili v sledečih dveh letih in nato v 3-letnih intervalih.
For motion sickness a light meal or snack before dosing is recommended, prolonged fasting before administration should be avoided. 
Za potovalno slabost je pred dajanjem priporočen manjši obrok ali priboljšek, podaljšanemu postu pred dajanjem pa se izognite.
Cerenia should be used with caution in animals suffering from or with predisposition for heart diseases. 
Posebna previdnost je potrebna pri uporabi zdravila Cerenia pri živalih, ki so predisponirane za kardiološke bolezni.
It is recommended to initiate treatment of emesis with Cerenia solution for injection. 
Priporoča se, da začnete zdravljenje slabosti s Cerenia raztopino za injiciranje.
Tablets are breakable along the score line on the tablet. 
Tablete se lahko prelomijo na zarezi.
1 ml of solution contains 10 mg maropitant (as maropitant citrate monohydrate). 
1 ml raztopine vsebuje 10 mg maropitanta (v obliki maropitantijevega citrata monohidrata)
Cerenia Solution for Injection: FAREVA AMBOISE Zone Industrielle, 29 route des Industries 37530 Pocé-sur-Cisse FRANCE 
Cerenia raztopina za injiciranje: FAREVA AMBOISE Zone Industrielle, 29 route des Industries
Amber molded glass type 1 vial, 20 ml, chlorobutyl rubber stopper and aluminium overseal with flip-off button. 
20 ml steklena viala, steklo tipa I, jantarjeve barve, zaprta s klorobutilnim gumijastim zamaškom in aluminijastim pokrovčkom z zaporko.
The tablets have a score line allowing the tablet to be halved, with the letters “MPT” and figures denoting the quantity of maropitant on one side, the reverse side is blank. 
s Črke 'MPT' in številke, ki označujejo količino maropitanta so na eni strani.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease. 
Maropitant se metabolizira v jetrih, zato je potrebna previdna uporaba pri psih in mačkah z jetrnimi obolenji.
Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range. 
Maropitant kaže linearno kinetiko po subkutanem dajanju v odmerku 0,5 - 2 mg/kg.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS 
NAVEDBA ZDRAVILNE UČINKOVIN(E) IN DRUGE(IH) SESTAVIN(E)
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t0.5) of 4.03 hours. 
Vrhu koncentracije sledi upadanje sistemske izpostavitve s polovičnim časom izločitve (t1/2) 4,03 ure.
Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS. 
Maropitant je močan in selektiven antagonist neurokinin receptorja (NK-1), ki inhibira vezavo substance P, tahikininski neuropeptid, v centralnem živčnem sistemu.
Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily. 
Cerenia se uporablja za zdravljenje ali preprečevanje bruhanja v obliki tablet ali raztopine za injiciranje enkrat dnevno.
To prevent vomiting induced by motion sickness, Cerenia tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below. 
Za preprečevanje bruhanja, ki je posledica slabosti zaradi vožnje, dajemo Cerenia tablete enkrat dnevno v odmerku 8 mg maropitanta na kg telesne mase, uporabimo število tablet, kot je navedeno v tabeli.
Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease. 
Maropitant se metabolizira v jetrih, zato je potrebna previdna uporaba pri bolnikih z jetrnimi obolenji.
Name and address of the manufacturers responsible for batch release 
Ime in naslov izdelovalca zdravila, odgovornega za sproščanje serije
To treat and/or prevent vomiting except motion sickness, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below. 
Za zdravljenje ter/ali preprečevanje bruhanja (razen slabosti zaradi vožnje) dajemo tablete Cerenia enkrat dnevno v odmerku 2 mg maropitanta na kg telesne mase, uporabimo število tablet, kot je navedeno v tabeli.
Renal clearance is a minor route of elimination, with less than 1% of an 8 mg/kg oral dose appearing in the urine as either maropitant or its major metabolite. 
Ledvični klirens predstavlja manjši delež izločitve, saj se manj kot 1 % peroralnega odmerka 8 mg/kg izloči z urinom kot maropitant ali njegov metabolit.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani
People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Osebe z znano preobčutljivostjo na maropitant naj zdravilo dajejo previdno.
Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite. 
Ledvični klirens predstavlja manjši delež izločanja, saj se manj kot 1 % subkutanega odmerka 1 mg/kg izloči z urinom kot maropitant ali njegov glavni presnovek.
Following repeated oral administration for five consecutive days at a daily dose of 2 mg/kg, accumulation was 151%. 
Pri ponavljajočem se peroralnem dajanju 5 zaporednih dni, dnevni odmerek 2 mg/kg, je akumulacija 151 %.
In dogs, Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily. 
Pri psih se Cerenia za zdravljenje ali preprečevanje bruhanja lahko uporablja v obliki tablet ali raztopine za injiciranje enkrat dnevno.
The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear, colourless to light yellow solution. 
1 ml raztopine za injiciranje vsebuje 10 mg maropitanta v obliki maropitantijevega citrata monohidrata, v obliki prozorne, brezbarvne do rahlo rumene raztopine.
In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
For the prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), (only for dogs 8 weeks of age or older). 
Preprečevanje slabosti povzročene zaradi kemoterapije ter zdravljenje in preprečevanje bruhanja (razen slabosti zaradi vožnje) (samo za pse, stare 8 tednov in več)
Estimates for the oral bioavailability of maropitant were 23.7% at 2 mg/kg and 37.0% at 8 mg/kg. 
Ocena peroralne biorazpoložljivosti maropitanta je 23,7 % pri 2 mg/kg in 37,0 % pri 8 mg/kg.Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenskem vnosu 1 - 2 mg/kg je od približno 4,4 do 7,0 l/kg.
A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity. 
Več in vitro poskusov je dokazalo, da se maropitant selektivno veže na NK1 receptor.
To treat or prevent vomiting, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below. 
Za zdravljenje ali preprečevanje bruhanja dajemo tablete Cerenia enkrat dnevno v odmerku 2 mg maropitanta na kg telesne mase, uporabimo število tablet, kot je navedeno v tabeli.
• For the prevention of nausea induced by chemotherapy. 
• Za preprečevanje slabosti, povzročene s kemoterapijo.
Sulphobutyl ether β-cyclodextrin (SBECD) Metacresol 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Sulfobutil eter β-ciklodekstrin (SBECD)
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Cerenia 10 mg/ml injection for dogs and cats maropitant 
Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke maropitant
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease. 
Maropitant se metabolizira v jetrih, zato je potrebna previdna uporaba pri psih z jetrnimi obolenji.
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax). 
Za farmakokinetični profil maropitanta, danega psom v enkratnem subkutanem odmerku 1 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 92 ng/ml; ta je dosežena v 0,75 ure po dajanju (tmax).
The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (Tmax). 
Za farmakokinetični profil maropitanta, danega psom v enkratnem peroralnem odmerku 2 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 81 ng/ml; ta je dosežena v 1,9 ure po dajanju (Tmax).
EU/2/06/062/005 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/06/062/005
Shelf life after first opening the immediate packaging: 28 days. 
Rok uporabnosti zdravila v pakiranju za prodajo: 3 leta Rok uporabnosti po prvem odpiranju stične ovojnine: 28 dni.
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax). 
Za farmakokinetični profil maropitanta, danega mačkam v enkratnem subkutanem odmerku 1 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 165 ng/ml; ta je dosežena v 0,32 ure po dajanju (tmax).
The safety of the veterinary medicinal product has not been established in dogs less than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than 8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating bitches. 
Varnost zdravila v odmerku 8 mg/kg (slabost med vožnjo) pri psih, mlajših od 16 tednov, v odmerku 2 mg/kg (bruhanje) pri psih, mlajših od 8 tednov, ter pri psicah v obdobju brejosti in laktacije ni bila dokazana.
Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose. 
Po dajanju odmerka 8 mg/kg se je lahko pred vožnjo pojavilo bruhanje, ponavadi v dveh urah po dajanju.
NAME OF MARKETING AUTHORISATION HOLDER 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Maropitant (as maropitant citrate monohydrate) 
Zdravilna učinkovina: Maropitant (v obliki maropitantijevega citrata monohidrata) 10 mg.
Cerenia 10 mg/ml solution for injection for dogs and cats 
Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke
The safety of the veterinary medicinal product has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats. 
Varnost zdravila pri psih, mlajših od 8 tednov, pri mačkah, mlajših od 16 tednov, ter pri psicah in mačkah v obdobju brejosti in laktacije ni bila dokazana.
Prevention of motion sickness 
Preprečevanje slabosti zaradi vožnje
• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness. 
• Za preprečevanje bruhanja, razen bruhanja, ki je posledica slabosti zaradi vožnje.
• For the prevention of vomiting except that induced by motion sickness. 
• Za preprečevanje bruhanja razen bruhanja, ki je posledica vožnje
Giving your dog a light meal or snack before administering the tablet could help preventing this effect. 
Ta učinek lahko preprečite tako, da psu ponudite manjši obrok ali prigrizek pred aplikacijo tablete.
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness) Dog body weight (kg) 
Preprečevanje slabosti povzročene s kemoterapijo Zdravljenje ter preprečevanje bruhanja (razen slabosti zaradi vožnje)
Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 
Z izjemo prehodnih reakcij na mestu injiciranja po subkutanem dajanju, so injiciranje odmerka do 5
AUTHORISATION 
FRANCIJA
PACKAGE LEAFLET: Cerenia 10 mg/ml solution for injection for dogs and cats 
NAVODILO ZA UPORABO Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke
The safety of Cerenia has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats. 
Varnost zdravila Cerenia pri psih, mlajših od 8 tednov, mačkah, mlajših od 16 tednov ter pri psicah in mačkah v obdobju brejosti in laktacije ni bila dokazana.
The responsible veterinarian should make a benefit-risk assessment before using Cerenia in dogs under 8 or 16 weeks of age, respectively, or in pregnant or lactating bitches. 
Pred uporabo zdravila Cerenia pri psih, mlajših od 8 oziroma 16 tednov ali pri psicah v obdobju brejosti in laktacije, mora odgovorni veterinar oceniti razmerje korist/tveganje.